Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2022 08:41 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome

ASHBURN, Va., March 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
March 10, 2022 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome

ASHBURN, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
March 01, 2022 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003 ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) --...
February 17, 2022 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome

Neopharm Gains Exclusive Rights to Commercialize QRX003 in IsraelSixth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb. 17, 2022 (GLOBE NEWSWIRE)...
February 10, 2022 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

- ER-Kim Gains Exclusive Rights to Commercialize QRX003 Across Central & Eastern Europe - Fifth Distribution Partnership Established Since Quoin’s NASDAQ Debut in October 2021 ASHBURN, Va., Feb....
January 26, 2022 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome

- OrphanDC Gains Exclusive Rights to Commercialize QRX003 in Key Countries in Latin America- Fourth Distribution Partnership Established Since Going Public in October 2021- Additional Territories in...
December 15, 2021 09:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome

ASHBURN, Va., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
November 11, 2021 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin’s Lead Asset, QRX003

ASHBURN, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, and...
November 08, 2021 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003

AFT Gains Exclusive Rights to Commercialize QRX003 in Australia and New Zealand ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”),...
November 04, 2021 09:25 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer

ASHBURN, Va., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right